APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATIONS:

The specification is changed as follows.

Page 30, first full paragraph:

The immunoselection method can be carried out in conjunction with debulking based on cell size, buoyant density, or a combination thereof. The selection method can select cells that express at least one marker associated with at least one cell lineage, which may be hemopoietic, hepatic, or mesenchymal. The [selection of] selected cells, their progeny, or more mature forms thereof can express at least one marker associated with at least one hepatic cell lineage. That lineage can be [parechymal] parenchymal cells or hepatocytes, or biliary cells. [Thu]Thus, the markers expressed by the cells can be CD14, CD34, CD38, CD117, ICAM, or combinations thereof.

IN THE CLAIMS:

The claims are amended as follows.

1. (amended)   A method of providing a composition comprising a mixture of cells derived from human liver tissue, which mixture comprises an enriched population of human liver progenitors, the method comprising:

(a)   providing a [substantially single] cell suspension of human liver tissue comprising a mixture of cells of varying sizes, including immature cells and mature cells; [and]

(b)   debulking the suspension under conditions that permit the removal of mature cells and those of relatively large size, while retaining immature cells and those of relatively small size[,]; and

(c)   selecting those cells which themselves, their progeny, or more mature forms thereof exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both,

to provide a mixture of cells comprised of an enriched population of human liver progenitors[which human liver progenitors themselves, their progeny, or more mature forms thereof exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both].

12. (amended) A method of providing a composition comprising an enriched population of human liver progenitors comprising:

      (a) providing a substantially single cell suspension of human liver tissue, and

      (b) subjecting the suspension to a positive or negative immunoselection, such that a mixture of cells is provided, which mixture of cells is comprised of an enriched population of human liver progenitors, which human liver progenitors themselves, their progeny, or more mature forms thereof exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both.

21. (amended) A composition comprising an enriched population of human liver progenitors, their progeny, or more mature forms thereof, which [human liver] exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both.

42. (amended) Isolated human [Human] liver progenitors, their progeny or more mature forms thereof which exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both.

43. (amended) Isolated human [Human] liver progenitors, their progeny or more mature forms thereof which exhibit the phenotype glycophorin A^-, $CD45^-$, alpha-fetoprotein^{+++}, albumin$^+$, and $ICAM^+$.

44. (amended) The isolated human liver progenitors of claim 43 which further express $CD14^+$, $CD34^{++}$, $CD38^{++}$, $CD117^+$, or combinations thereof.